Abstract: Atopic dermatitis (AD) is a multifactorial chronic remittent skin disease which requires long-term treatment. Pimecrolimus cream 1% is a nonsteroid selective inhibitor of infl ammatory cytokines and effective in the treatment of AD. Various clinical trials have shown its long-term safety and effi cacy in pediatric and adult patients suffering from mild to moderate AD. In this article we discuss data which has assessed the impact of AD on the patient's quality of life, and the consequent role of topical anti-infl ammatory therapy for longterm AD treatment.
Introduction
Atopic dermatitis (AD) is a chronic relapsing cutaneous disease characterized by dry and scaly skin, infl ammation, and intense itching. A point prevalence up to 30% in some industrialized countries and a steady increase in disease prevalence has been observed (Zuberbier et al 2006) . AD is more frequent in children; up to 20% of children are affected (Breuer et al 2005) . In adults, we have previously shown a point prevalence of 1.6% if current symptoms are considered (Worm et al 2006) . In addition to genetic factors, several trigger factors play a role in the development of AD (Leung and Bieber 2003) . These include allergens, microbial infections and, as recently shown, a disrupted skin barrier function (Marenholz et al 2006) . Accordingly, the treatment of AD is complex. One major basic measure is the regular usage of emollients. Furthermore, an anti-infl ammatory topical treatment is crucial to ending the itching-scratching cycle in affected patients. Corticosteroids have long been the standard treatment; calcineurin inhibitors now represent an additional treatment option. These offer long-term treatment, with stabilization of the chronic disease and an improvement in quality of life. This is of great importance, as it is known that AD has a greater impact on the quality of life than the other chronic skin diseases (Finlay and Khan 1994) . In addition, AD has a negative effect on the mental health of patients (Kiebert et al 2002) .
The recently published International Study Of Life with ATopic Eczema (ISOLATE) enrolled a total of 2002 patients from eight countries (France, Germany, Mexico, Netherlands, Poland, Spain, UK, and US). It presents for the fi rst time a large amount of quality of life data from affected AD patients. In the following we will review published clinical data on pimecrolimus and discuss its impact on the medical treatment of AD patients.
Structure and mechanism
Pimecrolimus is an ascomycin macrolactam derivative and was developed specifi cally for the treatment of infl ammatory skin diseases. By binding to the cytosolic receptor macrophilin-12 with high affi nity in T lymphocytes and forming a complex structure, the activity of the calcium dependent phosphatase calcineurin is blocked (Figure 1 ). The inhibition of calcineurin prevents from NF-AT dependent transcription of genes encoding the TH2-type cytokines IL-4 and IL-10 but also TH1-type cytokines IL-2 and IFN-γ. Pimecrolimus also decreases cytokine production from mast cells and infl uences the release of preformed mediators (Zuberbier et al 2001; Stuetz et al 2006) , while not affecting Langerhans cells (Meingassner et al 2003; Hoetzenecker et al 2004) .
Infants as well as children with extended atopic lesions are at high risk for local side effects and systemic absorption through the skin. Therefore, even minimal systemic absorption is an important safety aspect in infants. It is essential to exclude a possible systemic exposure to pimecrolimus when applied extensively on affected skin. However, previous pharmacokinetic studies in pedriatic patients have shown that systemic absorption of pimecrolimus is low, even in infants with large body surface area involvement (Harper et al 2001; Billich et al 2004; Draelos et al 2005; Meingassner et al 2005) . This low level of systemic absorption might be explained by the lipophilicity of the molecule and its high molecular weight (810 Da). Consequently, none of the systemic side effects associated with corticosteroids are expected with pimecrolimus.
Low systemic drug exposure in pimecrolimus treated infants was observed in an open-label, non-controlled study by Staab et al (2005) . The drug concentrations remained below 2 ng/mL in most cases (96%).
Clinical effi cacy and safety
The effi cacy and safety of pimecrolimus was analysed in various clinical studies related to short-and long-term management of AD and early intervention. Especially infants from 3 to 12 months and children up to 17 years of age were treated with pimecrolimus in the context of a novel nonsteroidal therapy. A signifi cant reduction in AD fl ares and pruritus, and a reduced application rate of topical corticosteroids were observed. In addition, systemic adverse events were rare, probably unrelated to pimecrolimus and not clinically relevant. In the majority of cases only local reactions occurred such as skin burning, fl ush symptomatic, and skin irritation, which normally disappeared within 1 week of treatment. On the other hand, a slightly increased incidence of viral 
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A n t i g e n P r e s e n t i n g C e l l A n t i g e n P r e s e n t i n g C e l l A n t i g e n P r e s e n t i n g C e l l P P cNF-AT cNF-AT cNF-AT cNF-AT NF-AT NF-AT P P Dephosphorylation blocked skin infections during the application of pimecrolimus has been shown; in this case, it is recommended to interrupt the application until the infection subsides (Eichenfi eld et al 2002; Kapp et al 2002; Wahn et al 2002; Ho et al 2003; Papp et al 2005) .
In adult patients, the treatment with pimecrolimus resulted also in a signifi cant reduction of topical corticosteroids usage. Furthermore, a pronounced reduction of pruritus and number of AD fl ares throughout the treatment period were observed. During therapy, quality of life also improved by 35% in patients using pimecrolimus, compared with 11% in the control group after 6 months (Meurer et al 2004) .
Currently, pimecrolimus has been approved as secondline therapy for the treatment of mild to moderate AD in non-immunocompromized children Ն2 years old and in adult patients. In 2005 the US Food and Drug Administration (FDA) modif ied the labeling of pimecrolimus (and tacrolimus) and included a black box warning which is the highest level of fi ve possible warning categories found in the package insert (Aaronson 2006) . This warning states that although a direct causal relationship has not been established, cases of malignancy (eg, skin and systemic) have been reported in patients treated with pimecrolimus, implying that this treatment bears a potential risk to patients if used in a long-term manner.
In contrast, data from randomized controlled studies suggest that pimecrolimus poses a lower risk of cancer than its vehicles or topical corticosteroids . In the case of pimecrolimus, out of 19,000 treated subjects 2 cases of cancers were reported (Hultsch 2005) , while out of 4000 subjects treated with corticosteroids or the comparator vehicle, 5 cases of cancers were described.
Impact of pimecrolimus on the quality of life
For many patients and caregivers of children with AD, the skin disease was not restricted only to the visible symptoms, but also had a severe impact on their overall quality of life.
The data from ISOLATE demonstrate that 75% of patients and caregivers regarded an improvement in their quality of life via effective AD control as most important (Zuberbier et al 2006) .
The characteristics of the study population are summarized in Figure 2 . About 50% of AD patients had been diagnosed in the fi rst 3 years of life, 24% after the age of 18 years. Over 50% suffered from moderate AD and 32% had a severe skin status. On average, every patient suffered from 9 fl ares per year with an average duration of 15 days, resulting in 136 fl are days per year. During a fl are, sleep disturbance occurred in an average of 7 nights and patients woke up almost twice a night.
Regarding the consequences of AD fl ares on patient's lifestyle, 86% of AD patients avoided at least one type of everyday activity during a fl are period, eg, swimming or wearing revealing clothes. In the same way parameters like school/work life, home life, and social life were altered during a fl are in almost 33% of the patients. In 9% of patients, school/work performance and productivity was infl uenced negatively. Patients with AD were absent about 2.5 days per year due to AD from school/work (Figure 3 ).
The ISOLATE data also demonstrate the emotional aspects of AD. At least 43% of the patients suffering from AD were fairly or very concerned about being seen in public while experiencing a fl are. More than 1 in 3 patients (36%) was impaired by a fl are in terms of selfconfi dence. Every second patient (51%) was always or sometimes unhappy or depressed respectively, while 27% of the patients had experienced bullying because of their AD (Table 1) .
Further aspects of patients' social lives were affected by AD fl ares, including relationships. About 30% of the patients or caregivers believed that either their or their child's AD had an effect on other household members. Twenty-one percent of adult patients indicated problems in forming relationships with a partner, and 12% had experienced diffi culties in established relationships due to an AD fl are. Furthermore, almost half of the patients (42%) felt embarrassed to be seen by their partner during a fl are ( Table 2) .
The ISOLATE data also demonstrated data on the "quality of life index for atopic dermatitis" (QoLIAD) for AD patients older than 13 years and the "parent's index of quality of life -atopic dermatitis" (PIQoL-AD) for caregivers of children aged 2-13 years. While adolescent and adult patients were worried (73%) and embarrassed (44%) about their appearance and did not want people to see their skin during a fl are (63%), the caregivers were concerned regarding the choice of clothes (71%) and had side effects of AD treatments in mind (64%) ( Table 3 ). The topical corticosteroid treatment especially worried about 89% of the caregivers and 83% of adolescent and adult patients.
The perceptions of patients and caregivers regarding topical AD treatment are shown in Table 4 . Skin atrophy after the application of topical corticosteroids still remains the most important anticipated side effect. 
Pimecrolimus for atopic dermatitis
The treatment with pimecrolimus was associated with a statistically signifi cant improvement in quality of life after 6 months of treatment compared to baseline in adult patients and caregivers. Interestingly, those caregivers who had previously reported concerns about local treatment with corticosteroids reported a signifi cantly greater improvement in quality of life than did those without such concerns. The application of corticosteroids on the other hand was less frequent and for shorter periods than recommended by the doctor. This is in line with previous studies showing the steroid sparing effect during long-term pimecrolimus treatment (Meurer et al 2004) .
Other recent studies have also reported the positive impact of pimecrolimus therapy on patients' quality of life (McKenna et al 2006; Sunderkötter et al 2006) . The data were assessed with the "Dermatology Life Quality Index" (DLQI) and the "Children's Dermatology Life Quality Index" (CDLQI) respectively and the PIQoL-AD. In the course of treatment a signifi cant improvement in the quality of life could be demonstrated (DLQI p Ͻ 0.0001, PIQoL-AD p Ͻ 0.052) together with an effective and well tolerated therapy.
Conclusion
AD is one of the most frequent chronic infl ammatory skin diseases, and it has a great impact on the quality of life on affected patients. Data from the ISOLATE study have allowed for the fi rst time a detailed analysis of social and emotional consequences in AD patients. The severity of these consequences indicates the necessity of effective treatment of AD. These consequences can be alleviated via long-term topical treatment with topical calcineurin inhibitors. 
